BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Biotie Shares Drop as Roche Passes on 5-HT6 Drug SYN120
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Biotie Shares Drop as Roche Passes on 5-HT6 Drug SYN120
June 27, 2012
By
Cormac Sheridan
No Comments
Shares in Biotie Therapies Oyj dropped nearly 10 percent Tuesday on news that Roche Holding AG decided not to exercise an option on its selective serotonin (5-hydroxytryptamine) receptor subtype 6 (5-HT6) antagonist SYN-120.
BioWorld